Steger G - Search Results

1

Poly(I).poly(C), a potential drug carrier for the antitumor agent mitoxantrone: in vitro drug binding study.

Eichler HG, Mader R, Blöchl-Daum B, Steger G, Rainer H. Eichler HG, et al. Among authors: steger g. Cancer Chemother Pharmacol. 1987;20(1):81-2. doi: 10.1007/BF00252966. Cancer Chemother Pharmacol. 1987. PMID: 3621457

2

Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration.

Eichler HG, Blöchl-Daum B, Mader R, Rainer H, Steger G, Dittrich C, Moser K, Ehninger G. Eichler HG, et al. Among authors: steger g. Chemotherapy. 1987;33(3):157-9. doi: 10.1159/000238488. Chemotherapy. 1987. PMID: 3595257 Clinical Trial.

3

Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation.

Blöchl-Daum B, Eichler HG, Rainer H, Jakesz R, Salzer H, Steger G, Schüller J, Günther E, Proksch B, Ehninger G. Blöchl-Daum B, et al. Among authors: steger g. Eur J Cancer Clin Oncol. 1988 Jul;24(7):1133-8. doi: 10.1016/0277-5379(88)90119-8. Eur J Cancer Clin Oncol. 1988. PMID: 3416898

4

Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation.

Blöchl-Daum B, Eichler HG, Rainer H, Jakesz R, Salzer H, Steger G, Schüller J, Günther E, Proksch P, Ehninger G. Blöchl-Daum B, et al. Among authors: steger g. Onkologie. 1987 Feb;10(1):54-6. doi: 10.1159/000216369. Onkologie. 1987. PMID: 3295627

5

[Interferon alpha 2C in the treatment of 2 patients with AIDS-associated Kaposi sarcoma].

Steger G, Dittrich C, Eichler HG, Flener R, Moser K. Steger G, et al. Wien Klin Wochenschr. 1987 Feb 20;99(4):120-3. Wien Klin Wochenschr. 1987. PMID: 3577187 German.

6

Cisplatin-induced renal effects and thromboxane A2 receptor blockade.

Dorner GT, Pehamberger H, Kornek G, Steger G, Müller M, Wolzt M, Kletter K, James P, Breiteneder H, Eichler HG, Blöchl-Daum B. Dorner GT, et al. Among authors: steger g. Eur J Clin Invest. 1997 Oct;27(10):836-9. doi: 10.1046/j.1365-2362.1997.2060753.x. Eur J Clin Invest. 1997. PMID: 9373762 Clinical Trial.

7

Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia.

Reinisch W, Willheim M, Hilgarth M, Gasché C, Mader R, Szepfalusi S, Steger G, Berger R, Lechner K, Boltz-Nitulescu G, et al. Reinisch W, et al. Among authors: steger g. J Clin Oncol. 1994 Oct;12(10):2146-52. doi: 10.1200/JCO.1994.12.10.2146. J Clin Oncol. 1994. PMID: 7931486 Clinical Trial.

8

Breast cancer chemoprevention - a vision not yet realized.

Blaha P, Dubsky P, Fitzal F, Bachleitner-Hofmann T, Jakesz R, Gnant M, Steger G. Blaha P, et al. Among authors: steger g. Eur J Cancer Care (Engl). 2009 Sep;18(5):438-46. doi: 10.1111/j.1365-2354.2008.00951.x. Epub 2009 Jul 20. Eur J Cancer Care (Engl). 2009. PMID: 19686352 Review.

9

Aneuploidy fraction but not DNA index is important for the prognosis of patients with stage I and II breast cancer--10-year results.

Gnant MF, Blijham GH, Reiner A, Schemper M, Reynders M, Schutte B, van Asche C, Steger G, Jakesz R. Gnant MF, et al. Among authors: steger g. Ann Oncol. 1993 Sep;4(8):643-50. doi: 10.1093/oxfordjournals.annonc.a058618. Ann Oncol. 1993. PMID: 8240995 Free article.

10

Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer.

Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlböck M, Steger G. Jakesz R, et al. Among authors: steger g. J Clin Oncol. 1999 Jun;17(6):1701-9. doi: 10.1200/JCO.1999.17.6.1701. J Clin Oncol. 1999. PMID: 10561206 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

451 results

Search Page

Filters